ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >PI3K / Akt / mTOR >PI3K inhibitor >IPI 145

IPI 145

CAS No.: 1201438-56-3

Chemical Name:: IPI 145

Synonyms: Duvelisib;IPI-14;CS-680;IPI 145;IPI-145;IPI-145, >=98%;IPI-145 INK197;IPI 145 USP/EP/BP;IPI-145 (INK-1197);DUVELISIB (IPI-145)

CBNumber:: CB32645143

Molecular Formula:: C22H17ClN6O

Molecular Weight:: 416.86

MOL File:: 1201438-56-3.mol

MSDS File:: SDS

Modify Date:: 2024/5/22 15:18:35

Request For Quotation

IPI 145 Properties

Melting point	205-206o C
Boiling point	757.8±60.0 °C(Predicted)
Density	1.474±0.06 g/cm3(Predicted)
storage temp.	-20°C
solubility	Soluble in DMSO (up to at least 25 mg/ml)
form	White solid.
pka	10.05±0.10(Predicted)
color	White
Stability	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

SAFETY

Risk and Safety Statements

Symbol(GHS)	GHS08
Signal word	Danger
Hazard statements	H360

IPI 145 Chemical Properties,Uses,Production

Uses

IPI 145 is an 1,2-dihydroisoquinolin-1(2H)-one derivative and has been developed as a modulator of PI3 kinase.

brand name

Copiktra

General Description

Class: lipid kinase; Treatment: CLL, SLL, FL; Other name: INK1197, IPI145; Oral bioavailability = 42%; Elimination half-life = 4.7 h; Protein binding = 98%

Pharmacokinetics

The recommended dose of duvelisib is 25 mg twice daily, much lower than that of idelalisib (150 mg, bid). Duvelisib is rapidly absorbed, with a peak concentration after 1–2 h. Following the administration of 25 mg of duvelisib, the absolute bioavailability in healthy volunteers is 42%. It is eliminated with a short half-life of 4.7 h, thus requiring twice daily administration.

target

PI3Kγ/δ

IC 50

IC 50 of IPI 145

Metabolism

Duvelisib is primarily metabolized by CYP3A4 to give a monooxidation product, IPI-656, which has no pharmacologically relevant activity.
Metabolic pathway of duvelisib in humans

IPI 145 Preparation Products And Raw materials

Raw materials

Preparation Products

IPI 145 Suppliers

Global( 171)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
A.J Chemicals	91-9810153283	New Delhi, India	6124	58	Inquiry
CLEARSYNTH LABS LTD.	+91-22-45045900	Hyderabad, India	6351	58	Inquiry
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	China	32760	60	Inquiry
career henan chemical co	+86-0371-86658258 +8613203830695	China	29898	58	Inquiry
BOC Sciences	+1-631-485-4226	United States	19553	58	Inquiry
Chongqing Chemdad Co., Ltd	+86-023-6139-8061 +86-86-13650506873	China	39916	58	Inquiry
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	United States	19892	58	Inquiry
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	China	24639	58	Inquiry
AFINE CHEMICALS LIMITED	+86-0571-85134551	China	15395	58	Inquiry
Baoji Guokang Bio-Technology Co., Ltd.	0917-3909592 13892490616	China	9322	58	Inquiry

Supplier	Advantage
A.J Chemicals	58
CLEARSYNTH LABS LTD.	58
ATK CHEMICAL COMPANY LIMITED	60
career henan chemical co	58
BOC Sciences	58
Chongqing Chemdad Co., Ltd	58
TargetMol Chemicals Inc.	58
Dideu Industries Group Limited	58
AFINE CHEMICALS LIMITED	58
Baoji Guokang Bio-Technology Co., Ltd.	58

A small-molecule inhibitor: IPI 145(Duvelisib)
Duvelisib (IPI 145) is a small-molecule inhibitor of phosphatidylinositol-3 kinase that has been developed as an oral treatmen....
Dec 27，2023

IPI 145 Spectrum

IPI 145(1201438-56-3)¹HNMR

1201438-56-3(IPI 145)Related Search:

Silicone oil Zafirlukast Sunitinib Malate Oxaprozin Pioglitazone hydrochloride

Calcium lactate Selumetinib MK-2206 2HCl Alpelisib (BYL719) CAL-101

Ibrutinib Ruxolitinib

chevron_left

1of3

chevron_right

IPI-145 IPI-145 (INK-1197) IPI-145 INK197 8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone IPI-145, >=98% Duvelisib (IPI-145, INK1197) DUVELISIB (IPI-145) 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]- 8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone Duvelisib (IPI-145, INK1197) Duvelisib INK 1197 IPI 145 IPI 145 (Duvelisib) IPI-145, INK 1197, Duvelisib IPI-145 INK197;DUVELISIB (IPI-145) IPI-14 DUVELISIB (IPI-145, INK1197);IPI 145; IPI145 IPI145; IPI 145; IPI-145. INK-1197; INK 1197; INK1197;DUVELISIB (IPI-145; INK1197) CS-680 8-chloro-2-phenyl-3-[(1s)-1-(7h-purin-6-ylamino)ethyl]isoquinolin-1-one IPI-145 (Duvelisib, INK1197) Duvelisib, 98%, a novel and selective PI3K δ/γ inhibitor DUVELISIB, 1201438-56-3, DUVELISIB [USAN], SURECN153543, UNII-610V23S0JI, IPI145, CHEMBL3039502, MOLPORT-028-600-025 IPI 145 USP/EP/BP Duvelisib IPI-145, INK197,Duvelisib INK-1197,Phosphoinositide 3-kinase,IPI 145,IPI145,inhibit,Duvelisib,PI3K,INK 1197,Inhibitor Dosulepin Impurity 3 (Dosulepin EP Impurity C) 1201438-56-3 201438-56-3 reference inhibitors Inhibitors